Updated Oct 27, 9:55 PM · 60 sources analyzed
Key Takeaways
Sanofi quietly terminated its NK cell engager AML program SAR443579 with no data disclosed, leaving portfolio rationale unclear.
Recursion Pharmaceuticals completed its Phase 2 REC-994 trial in cerebral cavernous malformation; a data readout will test its AI platform thesis.
Bayer's finerenone Phase 3 in CKD plus type 1 diabetes is complete; a positive readout could support label expansion beyond the current type 2 diabetes indication.
🏆 Winner
Bayer — finerenone Phase 3 completion in CKD/type 1 diabetes sets up a potential label expansion readout for an already-commercial asset
📉 Loser
Sanofi — termination of the SAR443579 NK cell engager AML program with no data disclosure signals a quiet but notable pipeline retreat
🔭 Watch Next
Recursion Pharmaceuticals' REC-994 Phase 2 data in cerebral cavernous malformation, expected at a neurology conference in Q4 2026 or early 2027, will be the most consequential platform validation event visible in today's sources.
Sanofi Terminates NK Cell Engager AML Program Mid-Study
Sanofi discontinued its Phase 1/2 study of SAR443579, a natural killer cell engager (a bispecific antibody designed to redirect immune NK cells to kill cancer cells), in combination with other agents for acute myeloid leukemia. The trial was terminated with no efficacy or safety data released publicly, leaving the program's fate unclear. NK cell engager programs are a crowded and competitive space, and Sanofi's exit signals either a portfolio prioritization decision or an undisclosed signal from early data.
ClinicalTrials.gov ↗Sanofi
SAR443579 in Acute Myeloid Leukemia
The Phase 1/2 study (NCT06508489) was terminated. No efficacy or safety data have been released publicly; the reason for termination was not disclosed in the registry record.
Why it matters
A terminated Phase 1/2 with no data disclosure is a black box — investors and BD teams cannot distinguish a clean portfolio cull from a data-driven kill. Sanofi will need to clarify the rationale; silence in AML, where unmet need is high and rivals are advancing, is not a good look for this franchise.
What to watch
Watch for Sanofi to disclose termination rationale at an upcoming investor day or AML conference presentation, and monitor whether any pipeline assets fill the hematology gap in their 2027 guidance.
Recursion Pharmaceuticals
REC-994 in Cerebral Cavernous Malformation
The two-part, randomized, double-blind, placebo-controlled Phase 2 study (NCT05085561) testing REC-994 at 200 mg and 400 mg versus placebo in cerebral cavernous malformation has been marked completed. Full numerical efficacy and safety data have not been released in the registry record.
Why it matters
REC-994 is a proof-of-concept asset for Recursion's platform thesis — a rare neurological disease with no approved therapies and a clear biological rationale. Study completion without a simultaneous data readout suggests results may be staged for a conference presentation, and the market will scrutinize whether the platform delivered on its promise.
What to watch
Watch for REC-994 Phase 2 data presentation at a neurology conference or Recursion investor event in Q4 2026 or early 2027.
Annexon Biosciences
ANX007 in Geographic Atrophy (age-related macular degeneration)
The Phase 2 study (NCT04656561) evaluating intravitreal injections of ANX007 to reduce geographic atrophy lesion growth has been marked completed. No efficacy or safety data have been released in the registry record.
Why it matters
Annexon is a small-cap company where this GA program carries significant pipeline weight. Completion without data release creates near-term uncertainty; the readout will test whether complement C1q inhibition via intravitreal delivery can carve a niche against entrenched complement pathway competitors.
What to watch
Watch for ANX007 Phase 2 data disclosure at a retinal disease conference such as AAO or ASRS in the next two to three quarters.
Bayer
Finerenone in Chronic Kidney Disease with Type 1 Diabetes
The Phase 3 study (NCT05901831) evaluating finerenone in people with chronic kidney disease and type 1 diabetes has been marked completed. Full efficacy and safety data have not been released in the registry record.
Why it matters
This is a straightforward label-expansion play for an already-approved asset. The commercial upside is real but bounded — type 1 diabetic CKD is a smaller population than type 2, and Bayer will need clean efficacy and safety data to support a supplemental filing. Investors should note finerenone faces increasing pressure from SGLT2 inhibitors in the broader CKD space.
What to watch
Watch for Bayer to present finerenone type 1 diabetes data at a nephrology or endocrinology congress such as ASN Kidney Week, expected in late 2026 or early 2027.
The Phase 1/2 study (NCT06508489) was terminated. No efficacy or safety data have been released publicly; the reason for termination was not disclosed in the registry record.
Why it matters
Termination of a multi-cohort NK cell engager program in AML tightens the competitive field and raises questions about whether the mechanism or this specific asset failed to deliver early signals.
Analysis
A terminated Phase 1/2 with no data disclosure is a black box — investors and BD teams cannot distinguish a clean portfolio cull from a data-driven kill. Sanofi will need to clarify the rationale; silence in AML, where unmet need is high and rivals are advancing, is not a good look for this franchise.
What to watch
Watch for Sanofi to disclose termination rationale at an upcoming investor day or AML conference presentation, and monitor whether any pipeline assets fill the hematology gap in their 2027 guidance.
The two-part, randomized, double-blind, placebo-controlled Phase 2 study (NCT05085561) testing REC-994 at 200 mg and 400 mg versus placebo in cerebral cavernous malformation has been marked completed. Full numerical efficacy and safety data have not been released in the registry record.
Why it matters
Completion of this study means Recursion should have data in hand; public disclosure of results will be a key read on whether its AI-driven drug discovery platform can translate computational hits into clinical outcomes.
Analysis
REC-994 is a proof-of-concept asset for Recursion's platform thesis — a rare neurological disease with no approved therapies and a clear biological rationale. Study completion without a simultaneous data readout suggests results may be staged for a conference presentation, and the market will scrutinize whether the platform delivered on its promise.
What to watch
Watch for REC-994 Phase 2 data presentation at a neurology conference or Recursion investor event in Q4 2026 or early 2027.
The Phase 2 study (NCT04656561) evaluating intravitreal injections of ANX007 to reduce geographic atrophy lesion growth has been marked completed. No efficacy or safety data have been released in the registry record.
Why it matters
Geographic atrophy is an increasingly contested indication following approvals of pegcetacoplan and avacincaptad pegol; ANX007's complement C1q inhibition (blocking a protein that triggers nerve cell death) represents a differentiated mechanism that will need to show meaningful lesion growth reduction to compete.
Analysis
Annexon is a small-cap company where this GA program carries significant pipeline weight. Completion without data release creates near-term uncertainty; the readout will test whether complement C1q inhibition via intravitreal delivery can carve a niche against entrenched complement pathway competitors.
What to watch
Watch for ANX007 Phase 2 data disclosure at a retinal disease conference such as AAO or ASRS in the next two to three quarters.
The Phase 3 study (NCT05901831) evaluating finerenone in people with chronic kidney disease and type 1 diabetes has been marked completed. Full efficacy and safety data have not been released in the registry record.
Why it matters
Finerenone (Kerendia) is already approved for CKD with type 2 diabetes; a positive readout in type 1 diabetes would meaningfully expand the addressable patient population and strengthen the product's long-term commercial case.
Analysis
This is a straightforward label-expansion play for an already-approved asset. The commercial upside is real but bounded — type 1 diabetic CKD is a smaller population than type 2, and Bayer will need clean efficacy and safety data to support a supplemental filing. Investors should note finerenone faces increasing pressure from SGLT2 inhibitors in the broader CKD space.
What to watch
Watch for Bayer to present finerenone type 1 diabetes data at a nephrology or endocrinology congress such as ASN Kidney Week, expected in late 2026 or early 2027.
The Phase 1/2 study (NCT04686175) evaluating safety, tolerability, and efficacy of INZ-701 in adults with ENPP1 deficiency has been marked completed. Detailed efficacy data have not yet been released in the registry record.
Why it matters
INZ-701 targets an ultra-rare disease with no approved treatments; any clean efficacy signal in this completed study would support a potential registration pathway and validate Inozyme's platform in ENPP1-related conditions.
Analysis
Inozyme is a small-cap rare disease company where INZ-701 is the lead asset and essentially the entire investment thesis. Completion of the Phase 1/2 in adults is a necessary precursor to any pivotal program, and the data readout will determine whether the company can attract partnership interest or pursue an independent regulatory strategy.
What to watch
Watch for Inozyme to present INZ-701 adult data at a rare disease or metabolic bone disease conference and any subsequent communication about Phase 3 trial design or regulatory engagement.
Computationally Designed PDE4 Inhibitors Show Structural Promise for Psoriasis
Researchers used computational drug design methods to identify two novel phosphodiesterase-4 (PDE4) inhibitors — enzymes that regulate inflammation — as potential treatments for plaque psoriasis, reporting favorable predicted binding profiles compared to existing agents.
Why it matters
If validated in cellular and animal models, computationally guided PDE4 inhibitor design could yield candidates with improved selectivity or tolerability compared to approved agents like apremilast, which carry gastrointestinal side effect burdens that limit adherence.
Analysis
This is early-stage preprint science with no in vivo data disclosed, so it belongs firmly in the hypothesis-generating category. The PDE4 inhibitor space is not crowded at the discovery end, and dermatology BD teams at mid-sized biotechs should track whether these scaffolds advance to wet-lab validation.
What to watch
Watch for follow-up preprint or peer-reviewed publication reporting in vitro potency and selectivity data, which would be the next meaningful signal of translational viability.
UCB's Rozanolixizumab Completes Pediatric Myasthenia Gravis Safety Study
UCB completed a Phase 2/3 study (NCT06149559) evaluating the safety and tolerability of subcutaneous rozanolixizumab in pediatric patients aged 2 to under 18 years with generalized myasthenia gravis, though no data have been publicly released from the registry record.
Why it matters
Rozanolixizumab (Rystiggo) is already approved for adults with generalized myasthenia gravis; demonstrating a pediatric safety profile would open a regulatory pathway for a label extension into a population with very limited treatment options.
Analysis
Pediatric extensions of approved FcRn inhibitors (drugs that prevent antibody recycling, reducing disease-causing antibodies) are becoming a competitive priority across MG, ITP, and other antibody-mediated diseases. UCB completing this study positions it to file a pediatric supplement ahead of competitors, which also carries regulatory incentives including potential exclusivity extensions.
What to watch
Watch for UCB to present pediatric rozanolixizumab data at the Myasthenia Gravis Foundation of America conference or a pediatric neurology meeting, and monitor for a supplemental BLA filing timeline.
Ketamine vs. Midazolam RCT Completes in Methamphetamine Use Disorder
A Phase 2 randomized controlled trial (NCT06496750) comparing IV ketamine to IV midazolam for treatment of moderate-to-severe methamphetamine use disorder at the University of Texas Southwestern has been marked completed, with no data yet released.
Why it matters
Methamphetamine use disorder has no FDA-approved pharmacotherapy; a positive ketamine signal — even in a small Phase 2 — would provide the first controlled evidence for a dissociative anesthetic in stimulant addiction and create a rationale for larger trials or novel ketamine formulations.
Analysis
This is a scientifically meaningful trial design using an active comparator (midazolam) to control for non-specific sedative effects, which is the correct methodological bar for ketamine research. Biotech companies and academic spinouts developing ketamine analogs or esketamine formulations for addiction should track this data closely — a positive result would validate the mechanism in a high-unmet-need indication.
What to watch
Watch for publication of results in an addiction medicine or psychiatry journal, which would set the evidentiary benchmark for any company seeking to build a Phase 3 program in methamphetamine use disorder.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.